NASDAQ:SXTP 60 Degrees Pharmaceuticals Q3 2025 Earnings Results & Report $0.88 -0.02 (-1.78%) As of 12:29 PM Eastern This is a fair market value price provided by Massive. Learn more. 60 Degrees Pharmaceuticals beat analyst earnings expectations but missed on revenue in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$2.64 versus the -$4.84 consensus estimate, while revenue of ($0.01) million fell short of the $0.38 million estimate by $0.39 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 13, 2025TimeBefore Market OpensConference Call4:00 PM ET 60 Degrees Pharmaceuticals EPS ResultsActual EPS-$2.64Consensus EPS -$4.84Beat/MissBeat by +$2.20One Year Ago EPSN/AEPS Beat Rate2 of last 8 quarters60 Degrees Pharmaceuticals Revenue ResultsActual Revenue($0.01) millionExpected Revenue$0.38 millionBeat/MissMissed by -$389.13 thousandYoY Revenue GrowthN/AUpcoming Earnings60 Degrees Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) 60 Degrees Pharmaceuticals Q3 2025 Earnings FAQ Did 60 Degrees Pharmaceuticals beat earnings estimates for Q3 2025? 60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported earnings of -$2.64 per share for Q3 2025, beating the consensus estimate of -$4.84. The report was announced on Thursday, November 13, 2025. What was 60 Degrees Pharmaceuticals' revenue for Q3 2025? 60 Degrees Pharmaceuticals reported revenue of ($0.01) million for Q3 2025, against a consensus estimate of $0.38 million. When is 60 Degrees Pharmaceuticals' next earnings date? 60 Degrees Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for 60 Degrees Pharmaceuticals on the company's earnings history page. 60 Degrees Pharmaceuticals Earnings Headlines60 Degrees Pharmaceuticals (NASDAQ:SXTP) versus Eyepoint Pharmaceuticals (NASDAQ:EYPT) Head to Head AnalysisOctober 14 at 4:15 AM | americanbankingnews.com60 Degrees Pharmaceuticals (NASDAQ:SXTP) Stock Price Down 0.9% - Time to Sell?October 8, 2026 | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)60 Degrees To Unblind Babesiosis Study In January 2027; Plans FDA Meeting Following Interim ReviewOctober 7, 2026 | rttnews.com60 Degrees Pharmaceuticals sets January 2027 babesiosis data readout and plans FDA pre-sNDA meetingOctober 7, 2026 | msn.com60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDAOctober 6, 2026 | globenewswire.comSee More 60 Degrees Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email. Email Address About 60 Degrees Pharmaceuticals60 Degrees Pharmaceuticals (NASDAQ:SXTP), Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for infectious and tropical diseases. The company’s lead product is Arakoda (tafenoquine), an oral antimalarial approved by the U.S. Food and Drug Administration for the prevention of malaria in adults. Arakoda is designed for use as a malaria-prophylaxis regimen before, during and after travel to areas where malaria is present. The product is marketed in the United States, and 60 Degrees Pharmaceuticals has also pursued opportunities to expand access through international partnerships and regulatory development. The company was founded in 2010 and is headquartered in Washington, D.C. In addition to its malaria business, 60 Degrees Pharmaceuticals has evaluated tafenoquine and related therapies for other infectious diseases, including babesiosis, an emerging tick-borne disease. Geoffrey Dow serves as the company’s chief executive officer.View 60 Degrees Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
